CLL-1.CAR T cells
Phase 1Cell therapy
CLL-1.CAR T cells is one of 7 biologic programs targeting Chimeric Antigen Receptor T-cell. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Chimeric Antigen Receptor T-Cell
#DrugCompanyPhaseTrials
1Immunoglobulin
SanofiPhase 3
Copiktra
SSecuraBio
Phase 1
FOLFOX
AstraZenecaPhase 1
FOLFIRI
AmgenPhase 1
Cd19x22 CAR T
UUniversity of Colorado, Denver
Phase 1
CYAD-101
CCelyad Oncology SA
Phase 1
CLL-1.CAR T cells
BBaylor College of Medicine
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chimeric Antigen Receptor T-cell1 trial
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
Active, not recruiting·—·Phase 1·NCT04219163·18 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CLL-1.CAR T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- BBaylor College of Medicine